Literature DB >> 20401336

Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach.

John P Fitzgerald1, Dennis McCarty.   

Abstract

Individual and organizational variables influence attitudes towards use of naltrexone, methadone, and buprenorphine for the treatment of alcohol and drug disorders. Prior research has not considered both sets of influences simultaneously. Hierarchical linear modeling tested the contribution of individual and organizational variables using data from the National Drug Abuse Treatment Clinical Trials Network treatment unit and workforce surveys (n = 2,269 staff nested within 247 treatment units). Individual-level variables consistently had more influence on attitudes, but a unique blend of variables existed for each medication. One predictor, support for psychiatric medications, influenced attitudes across all medications. Staff attitudes towards addiction medications varied significantly between treatment units. Implications for increasing the appropriate use of addiction medications are discussed.

Entities:  

Year:  2009        PMID: 20401336      PMCID: PMC2855198          DOI: 10.1037/a0013420

Source DB:  PubMed          Journal:  Psychol Serv        ISSN: 1541-1559


  35 in total

1.  Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Authors:  L Amass; J B Kamien; S K Mikulich
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  Staff beliefs about addiction treatment.

Authors:  R F Forman; G Bovasso; G Woody
Journal:  J Subst Abuse Treat       Date:  2001-07

Review 3.  Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders.

Authors:  William R Miller; Paula L Wilbourne
Journal:  Addiction       Date:  2002-03       Impact factor: 6.526

4.  A 3-year progress report on the implementation of LAAM in the United States.

Authors:  R A Rawson; A L Hasson; A M Huber; M J McCann; W Ling
Journal:  Addiction       Date:  1998-04       Impact factor: 6.526

Review 5.  Measuring treatment philosophy: a scale for substance abuse recovery programs.

Authors:  L A Kaskutas; T K Greenfield; T J Borkman; J A Room
Journal:  J Subst Abuse Treat       Date:  1998 Jan-Feb

6.  Pharmacological treatment of alcohol dependence: a review of the evidence.

Authors:  J C Garbutt; S L West; T S Carey; K N Lohr; F T Crews
Journal:  JAMA       Date:  1999-04-14       Impact factor: 56.272

7.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

Review 8.  Acamprosate in the treatment of alcohol dependence.

Authors:  Barbara J Mason
Journal:  Expert Opin Pharmacother       Date:  2005-10       Impact factor: 3.889

Review 9.  Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.

Authors:  Carmen Bouza; Magro Angeles; Angeles Magro; Ana Muñoz; José María Amate
Journal:  Addiction       Date:  2004-07       Impact factor: 6.526

10.  Physicians' opinions about medications to treat alcoholism.

Authors:  Tami L Mark; Henry R Kranzler; Xue Song; Peace Bransberger; Virginia H Poole; Scott Crosse
Journal:  Addiction       Date:  2003-05       Impact factor: 6.526

View more
  15 in total

1.  Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.

Authors:  Elizabeth Bromley; Derjung M Tarn; Michael McCreary; Brian Hurley; Allison J Ober; Katherine E Watkins
Journal:  J Subst Abuse Treat       Date:  2020-04-20

2.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

3.  Counselor Attitudes Toward Contingency Management for Substance Use Disorder: Effectiveness, Acceptability, and Endorsement of Incentives for Treatment Attendance and Abstinence.

Authors:  Lydia Aletraris; Jeff S Shelton; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2015-05-07

4.  Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use.

Authors:  Nora Jacobson; Julie Horst; Liam Wilcox-Warren; Alex Toy; Hannah K Knudsen; Randy Brown; Eric Haram; Lynn Madden; Todd Molfenter
Journal:  J Behav Health Serv Res       Date:  2020-10       Impact factor: 1.505

5.  Comparison of buprenorphine treatment for opioid dependence in 3 settings.

Authors:  Karen Miotto; Maureen Hillhouse; Roger Donovick; Jerry Cunningham-Rathner; Charlie Charuvastra; Matthew Torrington; Asher E Esagoff; Walter Ling
Journal:  J Addict Med       Date:  2012-03       Impact factor: 3.702

6.  Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections.

Authors:  Peter D Friedmann; Donna Wilson; Hannah K Knudsen; Lori J Ducharme; Wayne N Welsh; Linda Frisman; Kevin Knight; Hsiu-Ju Lin; Amy James; Carmen E Albizu-Garcia; Jennifer Pankow; Elizabeth A Hall; Terry F Urbine; Sami Abdel-Salam; Jamieson L Duvall; Frank J Vocci
Journal:  J Subst Abuse Treat       Date:  2014-10-14

7.  Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach.

Authors:  Amanda J Abraham; Traci Rieckmann; Thomas McNulty; Anne E Kovas; Paul M Roman
Journal:  Addict Behav       Date:  2011-01-28       Impact factor: 3.913

8.  From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

Authors:  Walter Ling; Petra Jacobs; Maureen Hillhouse; Albert Hasson; Christie Thomas; Thomas Freese; Steven Sparenborg; Dennis McCarty; Roger Weiss; Andrew Saxon; Allan Cohen; Michele Straus; Gregory Brigham; David Liu; Paul McLaughlin; Betty Tai
Journal:  J Subst Abuse Treat       Date:  2010-06

9.  Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.

Authors:  Kelly Alanis-Hirsch; Raina Croff; James H Ford; Kim Johnson; Mady Chalk; Laura Schmidt; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2015-11-06

10.  A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.

Authors:  Ruthanne Marcus; Martha J Bojko; Alyona Mazhnaya; Iuliia Makarenko; Sergii Filippovych; Sergii Dvoriak; Frederick L Altice; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2018-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.